NL-OMON20600已完成不适用
Immunogenicity and safety study of a third measles mumps rubella (MMR-3) vaccine dose in healthy young adults in The Netherlands
ational Institute for Public Health and the Environment (RIVM), Centre for Infectious Disease Control (CIb)0 个研究点目标入组 150 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 150
研究概览
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Healthy young adult 18-25 years of age
- •2. Previously been immunized with two doses of the MMR vaccine according to the Dutch
- •NIP (MMR-1 at ~14 months and MMR-2 at ~9 years)
排除标准
- •1. Medical conditions that will severely affect immunological responses to vaccinations,
- •such as, but not limited to, cancer or an immune disorder.
研究者
相似试验
进行中（未招募）
1 期
MMR-3 research; The effect of a third vaccination with the mumps, measles and rubella combination vaccine on the immunity against the mumps virus in healthy young adults.immunological response to an extra mumps immunization (in healthy volunteers)EUCTR2016-001104-36-NLRIVM147
已完成
4 期
Immunogenicity and safety study of a third measles mumps rubella (MMR-3) vaccine dose in healthy young adults in The NetherlandsMumps infectionparotitis10047438NL-OMON47906RIVM150
已完成
不适用
Study of safety and immunogenicity of Measles vaccine (Rouvax®) administered by transcutaneous route (France)Vaccine/immunisationInfections and InfestationsVaccinationISRCTN88861431World Health Organization (WHO)/Department of Immunisation, Vaccines and Biologicals (IVB) (Switzerland)
已完成
3 期
Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)MeaslesMumpsVaricellaRubellaNCT01536405Merck Sharp & Dohme LLC1,412
Unknown
4 期
Safety and Immunogenicity of Measles Vaccine, Varicella Vaccine and Hepatitis-A VaccineMeaslesHepatitis AVaricellaNCT03330171University of Witwatersrand, South Africa278